Molecular assay for K-ras

Thursday, 01 January, 2009 | Supplied by: QIAGEN Pty Ltd



Qiagen has launched a test to determine mutations of the K-ras gene, which can better define which metastatic colorectal cancer (CRC) patients will benefit from treatment with epidermal growth factor receptor (EGFR) inhibiting monoclonal antibodies, such as Amgen’s Vectibix (panitumumab) and Imclone/Bristol-Myers Squibb’s Erbitux (cetuximab).

The PyroMark Q24 K-ras Assay-Kit is CE marked for use in second-line treatment of metastatic CRC together with Erbitux of Vectibix. It can detect all major and minor known mutations in the K-ras codons 12, 13 and 61 and also allows the discovery of new mutations.

The assay is based on Pyrosequencing, a technology for short-length, high-resolution sequence analysis and quantification.

Pyrosequencing reads the actual target sequence and is claimed to be able to detect all known and unknown genetic variations in DNA target regions in which mutations occur. It provides built-in quality control, multiplex formats and is suitable for complex starting materials such as fixed tissue.

 

Online: www.qiagen.com
Phone: 03 9840 9800
Related Products

3M Petrifilm Plates and Plate Reader

The 3M Petrifilm Plates and Plate Reader are designed to distil the complexity, variability and...

3M Molecular Detection System

The 3M Molecular Detection System is designed to help save time and labour with its ready-to-use...

3M Clean-Trace ATP-based Hygiene Monitoring and Management System

The 3M Clean-Trace ATP-based Hygiene Monitoring and Management System features a Luminometer LM1...


  • All content Copyright © 2019 Westwick-Farrow Pty Ltd